Information Provided By:
Fly News Breaks for February 13, 2017
OMCL
Feb 13, 2017 | 07:29 EDT
Oppenheimer analyst Mohan Naidu expects Omnicell to report good traction and is particularly excited about the new XT System launch in December 16. Nonetheless, the analyst says he has to contemplate elongation of deals and implementations as customers delay deals in anticipation of XT general release in Q1. Naidu sees Omnicell's position in medication management strengthening with the XT introduction and would use any weakness in the shares pertaining to 1H17 guidance weakness as an entry point. He reiterates an Outperform rating and $44 price target on the shares.
News For OMCL From the Last 2 Days
There are no results for your query OMCL